Comparative Pharmacology
Head-to-head clinical analysis: HEXALEN versus MUSTARGEN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HEXALEN versus MUSTARGEN.
HEXALEN vs MUSTARGEN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Alkylating agent that crosslinks DNA, inhibiting DNA replication and transcription, and inducing apoptosis in rapidly dividing cells.
MUSTARGEN (mechlorethamine HCl) is a nitrogen mustard alkylating agent that forms cross-links between DNA strands, inhibiting DNA replication and transcription, leading to cell death.
260 mg/m2/day orally in 4 divided doses for 14 or 21 days of a 28-day cycle.
IV: 0.4 mg/kg or 12 mg/m² BSA as a single dose or divided into 0.1 mg/kg/day for 4 days.
None Documented
None Documented
Terminal elimination half-life is 12-13 hours; prolonged to 24 hours in renal impairment.
Terminal half-life: 30-60 minutes (rapidly inactivated); clinical context: very short due to rapid hydrolysis and alkylation, necessitating rapid administration after reconstitution.
Primarily renal and hepatic metabolism; 60-70% excreted in urine as unchanged drug and metabolites; 15-20% eliminated in feces via biliary secretion.
Renal: 50% as unchanged drug and metabolites; fecal: minor (<10%); biliary: minimal.
Category C
Category C
Alkylating Agent
Alkylating Agent